1[1]Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19and breast cancer risk [J].Int J Cancer, 2000, 87(2): 204-10.
2[2]Chetrite GS, Cortes-Prieto, Philippe JC, et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues [J]. J Steroid Biochem Mol Biol, 2000, 72:1-2.
3[3]Gos PE, Jarman M, Wilkinson JR, et al. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo:identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat J Steroid Biochem 1986, 24:619-622.
4[4]Dowseltt M, Goss PE, P owles TJ, et al. Jeffcoate SL, Coombes RC: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal brest cancer[J]. Res, 1987, 47:1957-1961.
5[5]Dowsett M, Cunningham DC, Stein RC, et al. Coombes RC: Does-related endocrine effects and pharmacokinetics or oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients [J]. Cancer Res, 1989, 49:1306-1312.
6[7]Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells [J].J Clin Endocrinol Metab, 1995, 80: 2918-2925.
7[8]Lonning PE. Pharmacology of new aromatase inhibitors Breast, 1996,5:202-208.
